Is KZIA or LCTX more undervalued in 2026?

CirclFi compares Kazia Therapeutics Limited (KZIA) and Lineage Cell Therapeutics, Inc. (LCTX) using 13 institutional-grade valuation models. KZIA has a Quality of Company score of 4.3/10 while LCTX scores 6.7/10.

Which is a better buy — KZIA or LCTX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do KZIA and LCTX valuations compare?

KZIA at $12.67 and LCTX at $1.33 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

KZIA vs LCTX Valuation Comparison 2026 — Intrinsic Value Analysis

KZIA

Biotechnology

Kazia Therapeutics Limited

Quality

4.3

out of 10

Value Trap

SAFE

Price

$12.67

Last close

Models

10/13

Active

LCTX

Biotechnology

Lineage Cell Therapeutics, Inc.

Quality

6.7

out of 10

Value Trap

SAFE

Price

$1.33

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	KZIA Fair Value	KZIA Upside	LCTX Fair Value	LCTX Upside
Bayesian DCF	Intrinsic	$5.76	-54.5%	$0.34	-74.5%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.43	-96.7%	$0.23	-82.9%
Dynamic NAV	Asset-Based	$2.95	-76.7%	$0.24	-82.3%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for KZIA vs LCTX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

KZIA vs LCTX — Which Stock Is More Undervalued?

LCTX scores higher with a 6.7/10 quality rating vs KZIA's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Kazia Therapeutics Limited (KZIA) and Lineage Cell Therapeutics, Inc. (LCTX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

KZIA currently trades at $12.67 with a QOC of 4.3/10, while LCTX trades at $1.33 with a QOC of 6.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).